Publication: Short term clinical outcomes for intravitreal dexamethasone implant in retinal vein occlusion patients [Retina ven tikanikligi olgularinda vitre içi deksametazon implantinin kisa dönem sonuçlar]
| dc.contributor.authors | Gülkas S., Sahin Ö. | |
| dc.date.accessioned | 2022-03-28T15:06:54Z | |
| dc.date.accessioned | 2026-01-11T07:21:39Z | |
| dc.date.available | 2022-03-28T15:06:54Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Purpose: To evaluate short term results of intravitreal dexamethasone implant for macular edema due to retinal branch vein occlusion (BRVO) and central vein occlusion(CRVO). Material and Methods: 31 eyes of 31 patients (15 male,16 female, mean age:59.7) with either BRVO or CRVO were assessed during 6 months prospectively .Treatment naive patients who had <20/50 (Snellen Chart) of visual acuity with ≥250 μm of central macular edema (CME) were enrolled. During follow-up, all subjects received 0.7 mg intravitreal injection once.At each visit (preop.,1-3 and 6 months later) subjects were evaluated with best corrected visual acuity (BCVA,logMAR), central macular thickness (CMT, optical coherence tomography), slit-lamp examination and intraocular pressure. Lens opacities were assessed according to lens opacities classification III (LOCSIII) Results: BCVA (logMAR) improved with mean difference score of 0.12 (p<0.01) and 0.05 (p>0.05) at 3rd and 6th month visits, respectively in CRVO subjects. CMT (μm) decreased with mean difference of 177.75 μm (p<0.05) and 10.75μm (p>0.05) at 3rd and 6th month visits, respectively in CRVO subjects. BCVA (logMAR) improved with mean difference score of 0.17 (p<0.01) and 0.22 (p<0.05) at 3rd and 6th month visits, respectively in BRVO subjects.CMT (μm) decreased with mean difference value of 130 μm (p<0.05) and 51.75 μm (p>0.05) at 3rd and 6th month visits, respectively in BRVO subjects. 3 of 31 eyes which had high IOP (≥21 mmHg) were controlled with medical treatment. 8 of 31 cases had mild cataract and none need cataract surgery. Conclusions: Intravitreal dexamethasone implant can be considered as long term effective choice for CME with BRVO and CRVO compared to intravitreal anti-VEGF treatment. Moreover, it is a safer treatment alternative than triamcinolone for side effect of steroids. © 2016 Gazi Eye Foundation. All Rights Reserved. | |
| dc.identifier.issn | 13001256 | |
| dc.identifier.uri | https://hdl.handle.net/11424/257175 | |
| dc.language.iso | tur | |
| dc.publisher | Gazi Eye Foundation | |
| dc.relation.ispartof | Retina-Vitreus | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Cataract | |
| dc.subject | Dexamethasone intravitreal implant | |
| dc.subject | Intraocular pressure | |
| dc.subject | Macular edema | |
| dc.subject | Retinal vein occlusion | |
| dc.title | Short term clinical outcomes for intravitreal dexamethasone implant in retinal vein occlusion patients [Retina ven tikanikligi olgularinda vitre içi deksametazon implantinin kisa dönem sonuçlar] | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 231 | |
| oaire.citation.issue | 3 | |
| oaire.citation.startPage | 227 | |
| oaire.citation.title | Retina-Vitreus | |
| oaire.citation.volume | 24 |
